After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. | After Sun ...

After falling 17 per cent since the start of the year to its March lows, the stock of the country’s largest pharmaceutical ...

Even inadvertent participation by a law clerk on a matter involving their future employer may call into question the court’s ...

Leqselvi is a medicine used to treat severe alopecia areata, manufactured by Sun Pharmaceutical. The generic name of the drug ...

Incyte's infringement lawsuit is claiming that Sun Pharma's drug infringes a US patent (No. 9,662,335) it holds on the use of ...

Emkay Global maintains a 'Buy' rating on Sun Pharma after the US Court of Appeals vacates the injunction against Leqselvi's ...

Sun Pharma stock rose more than 5 per cent intraday on Friday, April 11, after the company got a favorable order from a US ...

Dilip Shanghvi had said in February that the judgment was crucial for Sun Pharma's future course of action on this drug ...

Sun Pharmaceutical Industries stock ended 2.15 per cent higher on Friday after zooming by almost 5 per cent in the morning ...

Deal-making news last week included US drug developer KalVista Pharma signing a licensing agreement with Kaken Pharma to market its investigational hereditary angioedema (HAE) drug sebetralstat in ...

Emkay Global Financial Services, in a client note, described the development as “materially positive,” as it removes a key ...

A special congressional committee has recommended a $15 billion investment to boost the United States' biotech advantage over ...